Immune based therapies in cancer

Histology and Histopathology

Volumn 22, Issue 4-6, 2007, Pages 687-696

  Kruger C ^a   Greten, T F ^a   Korangy, Firouzeh ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Dendritic cell; T cell; Vaccine

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 2; K RAS PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELACINE; MELAN A; MELANOMA ANTIGEN 1; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; MUCIN 1; NY ESO 1 ANTIGEN; ONCOPHAGE; PLASMID DNA; PROTEIN P53; STEM CELL FACTOR; T LYMPHOCYTE ANTIGEN; TELOMERASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CROSS PRESENTATION; DYSPLASIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIFE EXPECTANCY; MELANOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR CELL LINE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 34247518239     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Asai T., Storkus W.J. and Whiteside T.L. (2000). Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin. Diagn. Lab. Immunol. 7, 145-154.
2. Banchereau J. and Palucka A.K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306.
3. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N., Pineiro L., Steinman R. and Fay J. (2001). Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458.
4. Banchereau J. and Steinman R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
5. Barrow C., Browning J., MacGregor D., Davis I.D., Sturrock S., Jungbluth A.A. and Cebon J. (2006). Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12, 764-771.
6. Berard F., Blanco P., Davoust J., Neidhart-Berard E.M., Nouri-Shirazi M., Taquet N., Rimoldi D., Cerottini J.C., Banchereau J. and Palucka A.K. (2000). Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192, 1535-1544.
7. Bernhard H., Disis M.L., Heimfeld S., Hand S., Gralow J.R. and Cheever M.A. (1995). Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55, 1099-1104.
8. Boczkowski D., Nair S.K., Snyder D. and Gilboa E. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472.
9. Boczkowski D., Nair S.K., Nam J.H., Lyerly H.K. and Gilboa E. (2000). Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028-1034.
10. Boon T., Cerottini J.C., Van den Eynde B., van der Bruggen P. and Van Pel A. (1994). Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365.
11. Brodie S.J., Patterson B.K., Lewinsohn D.A., Diem K., Spach D., Greenberg P.D., Riddell S.R. and Corey L. (2000). HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J. Clin. Invest. 105, 1407-1417.
12. Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., Dyrhaug M., Trachsel S., Moller M., Eriksen J.A. and Gaudernack G. (2006). Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother.
13. Cella M., Engering A., Pinet V., Pieters J. and Lanzavecchia A. (1997). Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782-787.
14. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T. and Falo L.D. Jr. (1996). Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283-287.
15. Cerundolo V., Hermans I.F. and Salio M. (2004). Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 5, 7-10.
16. Chang J.W., Peng M., Vaquerano J.E., Zhou Y.M., Clinton R.A., Hyun W.C., Giedlin M.A. and Leong S.P. (2000). Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res. 20, 1329-1336.
17. Conrad C. and Nestle F.O. (2003). Dendritic cell-based cancer therapy. Curr. Opin. Mol. Ther. 5, 405-412.
18. Coughlin C.M., Salhany K.E., Wysocka M., Aruga E., Kurzawa H., Chang A.E., Hunter C.A., Fox J.C., Trinchieri G. and Lee W.M. (1998). Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101, 1441-1452.
19. Coulie P.G., Brichard V., Van P.A., Wolfel T., Schneider J., Traversari C., Mattei S., De P.E., Lurquin C. and Szikora J.P. (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42.
20. Crossland K.D., Lee V.K., Chen W., Riddell S.R., Greenberg P.D. and Cheever M.A. (1991). T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J. Immunol. 146, 4414-4420.
21. Dhodapkar M.V., Krasovsky J., Osman K. and Geller M.D. (2003). Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J. Exp. Med. 198, 1753-1757.
22. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D. and Mulligan R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
23. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E. and Rosenberg S.A. (2002a). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854.
24. Dudley M.E., Wunderlich J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R.M., Marincola F.M., Leitman S.F., Seipp C.A., Rogers-Freezer L., Morton K.E., Nahvi A., Mavroukakis S.A., White D.E. and Rosenberg S.A. (2002b). A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243-251.
25. Dunn G.P., Old L.J. and Schreiber R.D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148.
26. Elliott G.T., McLeod R.A., Perez J. and Von Eschen K.B. (1993). Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol. 9, 264-272.
27. Ferrara N., Gerber H.P. and LeCouter J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
28. Figdor C.G., de Vries I.J., Lesterhuis W.J. and Melief C.J. (2004). Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480.
29. Fong L. and Engleman E.G. (2000). Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245-273.
30. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D. and Carbone D.P. (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103.
31. Garbe A.I., Vermeer B., Gamrekelashvili J., Wasielewski R., Greten F.R., Westendorf A.M., Buer J., Schmid R.M., Manns M.P., Korangy F. and Greten T.F. (2006). Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res. 66, 508-516.
32. Gilboa E. (1999). The makings of a tumor rejection antigen. Immunity 11, 253-270.
33. Glick R.P., Lichtor T., Mogharbel A., Taylor C.A. and Cohen E.P. (1997). Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41, 898-906; discussion 906-897.
34. + T cell immunity against B16 melanoma. J. Immunol. 171, 5940-5947.
35. Greenberg P.D. (1986). Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. J. Immunol. 136, 1917-1922.
36. Haque T., Amlot P.L., Helling N., Thomas J.A., Sweny P., Rolles K., Burroughs A.K., Prentice H.G. and Crawford D.H. (1998). Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J. Immunol. 160, 6204-6209.
37. Heslop H.E., Brenner M.K. and Rooney C.M. (1994). Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679-680.
38. Heslop H.E., Ng C.Y., Li C., Smith C.A., Loftin S.K., Krance R.A., Brenner M.K. and Rooney C.M. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551-555.
39. Inaba K., Metlay J.P., Crowley M.T. and Steinman R.M. (1990). Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 172, 631-640.
40. Jaffee E.M., Abrams R., Cameron J., Donehower R., Duerr D., Gossett J., Greten T., Grochow L., Hruban R., Kern S., Lillemoe K.D., O'Reilly S., Pardoll D.M., Sauter S., Weber C. and Yeo Y. (1998). A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum. Gene Therapy 9, 1951-1971.
41. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., Goemann M., Coleman J., Grochow L., Donehower R.C., Lillemoe K.D., O'Reilly S., Abrams R.A., Pardoll D.M., Cameron J.L. and Yeo C.J. (2001). Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156.
42. Jaffee E.M., Schutte M., Gossett J., Morsberger L.A., Adler A.J., Thomas M., Greten T.F., Hruban R.H., Yeo C.J. and Griffin C.A. (1998). Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4, 194-203.
43. Jonuleit H., Giesecke-Tuettenberg A., Tuting T., Thurner-Schuler B., Stuge T.B., Paragnik L., Kandemir A., Lee P.P., Schuler G., Knop J. and Enk A.H. (2001). A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J Cancer 93, 243-251.
44. Kim J.V., Latouche J.B., Riviere I. and Sadelain M. (2004). The ABCs of artificial antigen presentation. Nat. Biotechnol. 22, 403-410.
45. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., Thatcher J., Weinberg V., Wilson J., Darragh T., Jay N., Da Costa M. and Palefsky J.M. (2002). Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. 8, 1028-1037.
46. Korangy F., Ormandy L.A., Bleck J.S., Klempnauer J., Wilkens L., Manns M.P. and Greten T.F. (2004). Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin. Cancer Res. 10, 4332-4341.
47. Kusmartsev S. and Gabrilovich D.I. (2006). Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55, 237-245.
48. Laheru D. and Jaffee E.M. (2005). Immunotherapy for pancreatic cancer - science driving clinical progress. Nat. Rev. Cancer 5, 459-467.
49. Mackensen A., Herbst B., Chen J.L., Kohler G., Noppen C., Herr W., Spagnoli G.C., Cerundolo V. and Lindemann A. (2000). Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 86, 385-392.
50. Maraskovsky E., Daro E., Roux E., Teepe M., Maliszewski C.R., Hoek J., Caron D., Lebsack M.E. and McKenna H.J. (2000). In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96, 878-884.
51. Meidenbauer N., Marienhagen J., Laumer M., Vogl S., Heymann J., Andreesen R. and Mackensen A. (2003). Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170, 2161-2169.
52. Morse M.A., Zhou L.J., Tedder T.F., Lyerly H.K. and Smith C. (1997). Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. Ann. Surg. 226, 6-16.
53. Nagorsen D., Scheibenbogen C., Marincola F.M., Letsch A. and Keilholz U. (2003). Natural T cell immunity against cancer. Clin Cancer Res. 9, 4296-4303.
54. Neidhardt-Berard E.M., Berard F., Banchereau J. and Palucka A.K. (2004). Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res 6, R322-328.
55. Nestle F.O., Farkas A. and Conrad C. (2005). Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17, 163-169.
56. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F. and Korangy F. (2005). Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65, 2457-2464.
57. Pardoll D.M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev. Immunol. 13, 399-415.
58. Parmiani G., Testori A., Maio M., Castelli C., Rivoltini L, Pilla L., Belli F., Mazzaferro V., Coppa J., Patuzzo R., Sertoli M.R., Hoos A., Srivastava P.K. and Santinami M. (2004). Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res. 10, 8142-8146.
59. Peoples G.E., Gurney J.M., Hueman M.T., Woll M.M., Ryan G.B., Storrer C.E., Fisher C., Shriver C.D., Ioannides C.G. and Ponniah S. (2005). Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol 23, 7536-7545.
60. Prud'homme G.J. (2005). DNA vaccination against tumors. J. Gene Med. 7, 3-17.
61. Pulendran B., Banchereau J., Burkeholder S., Kraus E., Guinet E., Chalouni C., Caron D., Maliszewski C., Davoust J., Fay J. and Palucka K. (2000). Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165, 566-572.
62. Renkvist N., Castelli C., Robbins P.F. and Parmiani G. (2001). A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50, 3-15.
63. Richards J., Testori A., Whitman E., Mann G.B., Lutzky J., Camacho L., Parmiani G., Hoos A., Gupta R. and Srivastava P. (2006). Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. J. Clin. Oncol. 24, 8002.
64. Riddell S.R. and Greenberg P.D. (2000). T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J. Antimicrob. Chemother. 45 (Suppl T3), 35-43.
65. Riddell S.R., Walter B.A., Gilbert M.J. and Greenberg P.D. (1994). Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 14 (Suppl 4), S78-84.
66. Romani N., Gruner S., Brang D., Kampgen E., Lenz A., Trockenbacher B., Konwalinka G,, Fritsch P.O., Steinman R.M. and Schuler G. (1994). Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93.
67. Rosenberg S.A. and Dudley M.E. (2004). Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101 (Suppl 2), 14639-14645.
68. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C. and Seipp C.A. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676-1680.
69. Rosenberg S.A., Spiess P. and Lafreniere R. (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321.
70. Rosenberg S.A., Yang J.C., Robbins P.F., Wunderlich J.R., Hwu P., Sherry R.M., Schwartzentruber D.J., Topalian S.L., Restifo N.P., Filie A., Chang R. and Dudley M.E. (2003). Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother. 26, 385-393.
71. Sahin U., Tureci O. and Pfreundschuh M. (1997). Serological identification of human tumor antigens. Curr. Opin. Immunol. 9, 709-716.
72. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., Hodi F.S., Jaklitsch M., Mentzer S., Swanson S., Lukanich J., Bueno R., Wain J., Mathisen D., Wright C., Fidias P., Donahue D., Clift S., Hardy S., Neuberg D., Mulligan R., Webb I., Sugarbaker D., Mihm M. and Dranoff G. (2003). Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung caminoma. J. Clin. Oncol. 21, 624-630.
73. Sallusto F. and Lanzavecchia A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109-1118.
74. Savoldo B., Goss J., Liu Z., Huls M.H., Doster S., Gee A.P., Brenner M.K., Heslop H.E. and Rooney C.M. (2001). Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 72, 1078-1086.
75. Savoldo B., Cubbage M.L., Durett A.G., Goss J., Huls M.H., Liu Z., Teresita L., Gee A.P., Ling P.D., Brenner M.K., Heslop H.E. and Rooney C.M. (2002a). Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J. Immunol. 168, 909-918.
76. Savoldo B., Huls M.H., Liu Z., Okamura T., Volk H.D., Reinke P., Sabat R., Babel N., Jones J.F., Webster-Cyriaque J., Gee A.P., Brenner M.K., Heslop H.E. and Rooney C.M. (2002b). Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 100, 4059-4066.
77. Sawamura D., Abe R., Goto M., Akiyama M., Hemmi H., Akira S. and Shimizu H. (2005). Direct injection of plasmid DNA into the skin induces dermatitis by activation of monocytes through toll-like receptor 9. J Gene Med. 7, 664-671.
78. Schneeberger A., Wagner C., Zemann A., Luhrs P., Kutil R., Goos M., Stingl G. and Wagner S.N. (2004). CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 123, 371-379.
79. Schuler G., Schuler-Thurner B. and Steinman R.M. (2003). The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147.
80. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., Bender A., Feuerstein B., Fritsch P.O., Romani N. and Schuler G. (2002). Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195, 1279-1288.
81. Sheets E.E., Urban R.G., Crum C.P., Hadley M.L., Politch J.A., Gold M.A., Muderspach L.I., Cole G.A. and Crowley-Nowick P.A. (2003). Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol. 188, 916-926.
82. Simons J.W., Jaffee E.M., Weber C.E., Levitsky H.I., Nelson W.G., Carducci M.A., Lazenby A.J., Cohen L.K., Finn C.C., Clift S.M., Hauda K.M., Beck L.A., Leiferman K.M., Owens A.J., Piantadosi S., Dranoff G., Mulligan R.C., Pardoll D.M. and Marshall F.F. (1997). Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546.
83. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T. and Old L.J. (2005). Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5, 615-625.
84. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., Verjee S.S., Jones L.A. and Hershberg R.M. (2006). Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094.
85. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., Hodi F.S., Liebster L., Lam P., Mentzer S., Singer S., Tanabe K.K., Cosimi A.B., Duda R., Sober A., Bhan A., Daley J., Neuberg D., Parry G., Rokovich J., Richards L., Drayer J., Berns A., Clift S. and Dranoff G. (1998). Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 95, 13141-13146.
86. Sondak V.K., Liu P.Y., Tuthill R.J., Kempf R.A., Unger J.M., Sosman J.A., Thompson J.A., Weiss G.R., Redman B.G., Jakowatz J.G., Noyes R.D. and Flaherty L.E. (2002). Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 20, 2058-2066.
87. Sornasse T., Flamand V., De Becker G., Bazin H., Tielemans F., Thielemans K., Urbain J., Leo O. and Moser M. (1992). Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J. Exp. Med. 175, 15-21.
88. Sosman J.A., Unger J.M., Liu P.Y., Flaherty L.E., Park M.S., Kempf R.A., Thompson J.A., Terasaki P.I. and Sondak V.K. (2002). Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 20, 2067-2075.
89. Srivastava P. (2002). Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2, 185-194.
90. Srivastava P.K. (2005). Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr. Oncol. Rep. 7, 104-108.
91. Stevanovic S. (2002). Identification of tumour-associated T-cell epitopes for vaccine development. Nat. Rev. Cancer 2, 514-520.
92. Su Z., Dannull J., Heiser A., Yancey D., Pruitt S., Madden J., Coleman D., Niedzwiecki D., Gilboa E. and Vieweg J. (2003). Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63, 2127-2133.
93. Suzuki H., Graziano D,F., McKolanis J. and Finn O.J. (2005). T Cell-Dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin. Cancer Res. 11, 1521-1526.
94. Teague R.M., Sather B.D., Sacks J.A., Huang M.Z., Dossett M.L., Morimoto J., Tan X., Sutton S.E., Cooke M.P., Ohlen C. and Greenberg P.D. (2006). Interleukin-15 rescues tolerant CD8(+) T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12, 335-341.
95. Topalian S.L., Muul L.M., Solomon D. and Rosenberg S.A. (1987). Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102, 127-141.
96. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A. and Boon T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647.
97. Vaughan H.A., Svobodova S., Macgregor D., Sturrock S., Jungbluth A.A., Browning J., Davis I.D., Parente P., Chen Y.T., Stockert E., St Clair F., Old L.J. and Cebon J. (2004). Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin. Cancer Res. 10, 8396-8404.
98. Vonderheide R.H., Domchek S.M., Schultze J.L., George D.J., Hoar K.M., Chen D.Y., Stephans K.F., Masutomi K., Loda M., Xia Z., Anderson K.S., Hahn W.C. and Nadler L.M. (2004). Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. 10, 828-839.
99. Wada Y., Nakashima O., Kutami R., Yamamoto O. and Kojiro M. (1998). Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27, 407-414.
100. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D. and Riddell S.R. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044.
101. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99, 16168-16173.
102. Yu M. and Finn O.J. (2006). DNA vaccines for cancer too. Cancer Immunol. Immunother. 55, 119-130.
103. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C. and Coukos G. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213.
104. Zou W. (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307.